REVIEW Cabazitaxel is a semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity. Cabazitaxel binds to and stabilizes tubulin, resulting in the inhibition of microtubule depolymerization and cell division, cell cycle arrest in the G2/M phase, and the inhibition of tumor cell proliferation. Unlike other taxane compounds, this agent is a poor substrate for the membrane-associated, multidrug resistance (MDR), P-glycoprotein (P-gp) efflux pump and may be useful for treating multidrug-resistant tumors. In addition, cabazitaxel penetrates the blood-brain barrier (BBB).
Michielsen DP, Braeckman JG, Denis L. Cabazitaxel for the treatment of prostate cancer. Expert Opin Pharmacother. 2011 Apr;12(6):977-82.
Paller CJ, Antonarakis ES. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des Devel Ther. 2011 Mar 10;5:117-24.
Figg WD 2nd, Figg WD. Cabazitaxel: filling one of the gaps in the treatment of prostate cancer. Cancer Biol Ther. 2011 Jan 12;10(12):1233-4.
Diéras V, Lortholary A, Laurence V et al. Cabazitaxel in patients with advanced solid tumours: Results of a Phase I and pharmacokinetic study. Eur J Cancer. 2012 Sep 10. [Epub ahead of print].